沛嘉醫療-B(09996.HK)與美國inQB8達成合作 以探索治療結構性心臟病的創新解決方案
格隆匯6月10日丨沛嘉醫療-B(09996.HK)公佈,公司已與美國醫療技術孵化企業inQB8 Medical Technologies,LLC達成合作,以探索治療結構性心臟病的創新解決方案。該項合作包括公司向inQB8收購經導管三尖瓣置換術(TTVR)技術,該技術目前處於動物研究階段,而inQB8將與公司合作就此繼續進行設備開發。
該安排構成公司及inQB8各自擁有孵化公司的50%股權。根據該項合作,在共同開發結構性心臟病領域的新型產品及解決方案方面,公司將擁有該等技術的全球獨家優先權及權利。
董事會認為,與inQB8的合作將進一步擴大公司在經導管心臟瓣膜方面的產品組合,亦標誌着公司為實現成為該領域全球領先企業的目標而邁出又一步。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.